Astrazeneca opens a 300 million dollars cell therapy manufacturing factory in Maryland

Astrazeneca, as part of its current investment of $ 3.5 billion in American innovation, opened its first cell therapy factory operated by the United States in Maryland to help treat cancer patients.

The pharmaceutical giant based in the United Kingdom said that the new $ 300 million factory in Rockville symbolizes its confidence in the role of America as a “world leader in science, manufacturing and economic growth”.

“We understand the importance of doing what we do because life and health are at stake,” said Pam Cheng, executive vice-president of global operations in Astrazeneca, when the site official on Monday is opened. “We have chosen to do it in the state of Maryland because we believe in its incredible talent, its scientific leadership and the spirit of collaboration.”

Astrazeneca to withdraw his COVVI-19 vaccine around the world as a demand dive, the rare side effects revealed

Once in service, the site will use relatively new cancer treatment called CAR-T cell therapy to help treat blood cancers such as lymphoma and leukemia.

Andrew Gordon, a cancer survivor who was diagnosed in 2013 with a multiple myeloma, said that he had used Car-T cell therapy to fight against the disease after relapsed.

The multinational pharmaceutical company said that the new Maryland factory symbolizes its confidence in the role of America as a “world leader in science, manufacturing and economic growth”. (Fox News Digital / Fox News)

“It’s really the point of cancer research,” said Gordon. “As patients, we are so grateful to Astrazeneca for the work they are going to do here.”

Alternative cancer treatment could replace chemo and surgery suggests the study

The opening of the new factory comes after the comments of the past few weeks by the CEO of Astrazeneca, Pascal Sorot, about investing in America. He said the United States, compared to other areas like Europe, could be more attractive for pharmaceutical companies to invest due to its strong health care expenses, according to Reuters.

The Maryland site will use Car-T cell therapy, a relatively new cancer treatment, to help treat blood cancers such as lymphoma and leukemia. (Fox News Digital / Fox News)

“Europe spends a considerably lower part of GDP on innovative drugs than the United States and, therefore, delay in attraction [research and development] And manufacturing investments, putting its ability to protect the health of its own people in danger, “Sorot said in a statement.

What the financial markets cry about Trump’s prices

President Donald Trump was pressure for greater American innovation, recently praising a point of billions of dollars in American investment, including companies like Toyota, Amazon, Johnson & Johnson and others. In a list published by the White House of Trump’s victories during the first 100 days of his second term, he recognized the growing investment of Astrazeneca in American manufacturing.

The American operations of the pharmaceutical company now generate approximately 43% of its world revenues. (Fox News Digital / Fox News)

The investment of 3.5 billion dollars of the pharmaceutical company in the research and manufacture of the United States was announced for the first time in November. It also includes a research and development center in Massachusetts, specialized manufacturing in Texas and a new generation manufacturing plant for Maryland biologicals, according to the drug manufacturer.

Get Fox Affairs on the move by clicking here

While Astrazeneca’s American operations generate around 43% of its world revenues, the company hopes that, by 2030, the United States will represent half of its world revenues.

“With 4,200 US employees and more than 9 billion doses produced each year in our American manufacturing network, we believe that the future of advanced medicine should be built – and directed – from here at home,” wrote Astrazeneca in a statement.